Innovative Drug Manufacturer Standardizes on ICyte Platform to Ensure Launch Readiness

An emerging life sciences manufacturer was planning to launch a novel, oral therapy targeting 2.4 million patients in the highly genericized and competitive antipsychotic market. To bring its therapy to market, they would need to contract with both Medicaid and Medicare programs as well as enter into complex contracts with wholesalers and group purchasing organizations (GPOs). The Senior Vice President of Market Access, Policy and Government Affairs noted several significant concerns impacting launch success:

• Lack of a contract operations back-office capability that could ensure timely contracts with the various government programs and adhere to complex government pricing (GP) compliance
• Inability to monitor the effectiveness of costly patient services programs
• Limited visibility to retail inventory
• Inability to understand the pipeline liability to ensure accurate gross-to-net (GTN) accruals
• Experience and availability of staff and execute on complex gross-to-net (GTN) calculations

Download below!